Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.27) by 22.22 percent. This is a 12.5 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $1.001 million which missed the analyst consensus estimate of $1.046 million by 4.33 percent. This is a 124.44 percent increase over sales of $446.000 thousand the same period last year.
Lucid Diagnostics Q1 2024 Adj EPS $(0.21) Beats $(0.27) Estimate, Sales $1.001M Miss $1.046M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.